Dr. Reddy’s Laboratories Ltd today announced the launch of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg, a therapeutic equivalent generic version of Kuvan® (sapropterin dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the US Food and Drug Administration (USFDA).

“We are pleased to launch this generic version of Sapropterin Dihydrochloride Powder for Oral Solution, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.”

Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Solution, is available in 100 mg unit dose packets in a 30 count carton.

Please see the full prescribing information

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Articles

Dr. Reddy's Laboratories Announces Launch of Generic Version of Sapropterin Dihydrochloride Powder in US Market

Camber Pharmaceuticals is pleased to announce that it has launched 

 Injection, which is the generic version of Quelicin®

 Injection is indicated as an adjunct to 

, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or 

Succinylcholine ChlorideInjection is available from Camber in 200 mg/10mL (20mg/mL) - 25x 10mL Vials.

Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products. Its parent company, Hetero Drugs of Hyderabad India, is one of the world’s leading API and finished dosage manufacturers. Camber’s commitment to the consumer is to bring the highest quality generic pharmaceuticals to the market to improve quality of life through cost-effective medications.

Camber Pharma Launches Generic Quelicin®

®, the leading multimedia resource for pharmacy professionals, is excited to announce that it has expanded its Strategic Alliance Partnership (SAP) program roster with the addition of five new partners.

“This past quarter we have formed multiple partnerships with exceptional oncology and health system pharmacy leaders, strengthening our position in the pharmacy industry,” said Gil Hernandez, vice president of Pharmacy & Healthcare Communications, LLC, publisher of 

®. “As more organizations get added to our prestigious program, we can further develop the collaboration, research, and education of valuable information that is delivered through the 

Cancer Treatment Centers of America® (CTCA)

 is a nationally accredited oncology network of hospitals and outpatient care centers offering an integrated approach that combines surgery, radiation, chemotherapy, immunotherapy, and advancements in precision medicine with supportive therapies to manage adverse effects and enhance quality of life. With patient satisfaction scores that consistently rank among the highest for all cancer care providers, CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research.

 is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is the No. 11 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999.

 uses its voice to advocate for vulnerable populations and needed reforms in health care. Together, their 120,000 caregivers serve in 51 hospitals, 1,085 clinics, and a comprehensive range of health and social services across Alaska, California, Montana, New Mexico, Oregon, Texas, and Washington. Providence is committed to touching millions more lives and enhancing the health of the American West to transform care for the next generation and beyond.

 is a full-service acute care community hospital located in Somers Point, New Jersey, serving Atlantic and Cape May counties. With a mission of caring and respecting all patients, their families, and one another, Shore goes to extraordinary lengths to provide the highest quality care for all patients in a safe and compassionate environment.

 is the flagship academic medical center of UPMC. UPMC is an integrated global nonprofit health enterprise that has 90,000 employees, 40 hospitals with more than 8,000 licensed beds, 700 clinical locations including outpatient sites and doctors’ offices, a 3.8-million-member health insurance division, and commercial and international ventures. UPMC delivers life-changing medicine by harnessing the power of technology, translating science into cures, and accelerating the pace of innovation worldwide. As a tertiary care hospital, UPMC Presbyterian offers primary medical care, physician, pharmacist and nursing education, and a broad range of specialty health care services, including a renowned center for organ transplantation, heart and vascular medicine, oncology, geriatrics, orthopedics, Level I Regional Resource Trauma Center, endocrinology, certified Comprehensive Stroke Center, and more.

® SAP Program is an opportunity for community and specialty pharmacies, health systems, cancer centers, colleges of pharmacy, and advocacy groups to foster collaboration and open exchange of information among trusted peers for the benefit of patients and their families. As part of this joint effort, 

® works with the partners to inform and educate pharmacists in its 

® is the industry-leading multimedia pharmacy network of community, health system, oncology, and specialty pharmacy platforms, providing practical clinical and professional information pharmacists can use in their everyday practices when counseling patients and interacting with other health care providers. Each issue and the website contain articles and features covering industry trends, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law, and more. Additionally, 

™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

These nationally recognized health system and oncology leaders will join the esteemed SAP Program.

Pharmacy Times ® Adds Five Notable New Partners to its Strategic Alliance Partnership Program

), the industry leader in reverse pharmaceutical distribution services, today announced it has secured the Pharmaceutical Reverse Distribution Program (PRDP) with the 

Department of Defense— Continental United States (CONUS) and Outside Continental United States (OCONUS) covering the United States Army, Air Force, Navy and Marines. 

Pharma Logistics will service these agencies with programs focused on compliance, value and customer service while providing insight and analytics on the pharmaceutical returns process.

Pharma Logistics’ ability to provide best-in-class on-site services, credit collection, reconciliation and customer support was paramount in the selection for the Department of Defense. Services will be provided from its Chicago area headquarters and processing center.

“We are thrilled to continue our partnership with the OCONUS division and to resume our relationship with the CONUS division,” said President and CEO Michael Zaccaro. “By selecting Pharma Logistics for their reverse distribution service, these agencies are partnering with the leader in expired returns in the market today. Our focus on compliance and credit collection allows these service members to focus on their mission of patient care, not expired pharmaceutical returns.”

As an independent company with a singular focus on pharmaceutical returns, Pharma Logistics has a deep understanding of changing environments and regulations and offers various reverse distribution programs to fit the needs of its customers. In addition to servicing the Department of Defense, Pharma Logistics provides pharmaceutical returns to thousands of hospitals and independent retail pharmacies across the nation.

To learn more about how Pharma Logistics provides services to various 

Founded in 1996, Pharma Logistics is the trusted, proven industry leader in reverse pharmaceutical distribution services, including rapid credit, box and ship, onsite and drug take back programs. Pharma Logistics’ clients include hospital pharmacies, the Department of Defense and Veterans Health Administration, independent pharmacies, pharmacy chains and physicians’ offices. For more information about Pharma Logistics, visit the website at: pharmalogistics.com.

Pharma Logistics Wins Department of Defense Contract to Provide Pharmaceutical Reverse Distribution Services 

The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of evidence, science and medical innovation, today announced the appointment of veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, as president and chief executive officer.

O’Brien, who will assume the role on June 1, will be responsible for overseeing NPC’s policy research and communications capacity, partnerships with other health care organizations, and strategic vision.

O’Brien’s broad experience spans the private sector, academia and government. Prior to joining NPC, O’Brien was senior advisor to the U.S. Secretary of Health and Human Services and deputy assistant secretary of planning and evaluation (health policy). He has also held senior policy positions in the life sciences and managed care industries, including at CareFirst BlueCross BlueShield, was a career official at the Centers for Medicare & Medicaid Services (CMS) during the Obama administration, and served as a health policy fellow in the U.S. Senate.

“John brings to NPC a keen understanding of the issues facing both health care and the innovative biopharmaceutical industry, as well as a deep understanding of the important role NPC plays within the broader health care environment,” said Michael L. Ryan, Pharm.D., chair of NPC’s Board of Directors and senior vice president, Worldwide Value, Access, Pricing and Health Economics and Outcomes Research, Bristol Myers Squibb.

“John’s passion for health care and deep expertise will benefit NPC tremendously as it continues to explore, demonstrate and communicate the role and value of innovative biopharmaceuticals to achieve better patient health,” said Blasine Penkowski, chief strategic customer officer, Johnson & Johnson Health Care Systems. Penkowski led NPC’s executive search committee and served as the 2020 chair of NPC’s Board of Directors.

“I became a pharmacist because I was fascinated by the prescription medicines that made a difference in my family’s health. I have since dedicated my career to improving medication use,” O’Brien said. “Seeing my parents and tens of millions of other Americans get fully vaccinated against COVID-19 invigorates my appreciation for biopharmaceutical innovation. There has never been a more important time to continue NPC’s legacy of working with leading researchers to develop evidence demonstrating the value of medicines, and address tough policy questions about affordability and access.”

O’Brien will replace interim president and CEO Robert Dubois, M.D., Ph.D., who assumed the role after Dan Leonard left NPC in September 2020. Dubois will continue his role as chief science officer and executive vice president.

“I am honored to welcome John to the executive leadership team at NPC. His proven track record in the national health policy community and broad experience across health care will be central to NPC’s ongoing pursuit of sound evidence and forward-looking thinking,” Dubois said.

O’Brien earned his doctorate in pharmacy at Nova Southeastern University, his master’s degree in public health at the Johns Hopkins Bloomberg School of Public Health, and studied pharmacy and public policy at the University of Florida. His post-graduate experience includes the American Society of Health-System Pharmacists (ASHP) Executive Fellowship in Association Management and Leadership and the America’s Health Insurance Plans (AHIP) Certified Health Insurance Executive Fellowship.

He has held a number of academic appointments, including senior fellow at the USC-Schaeffer Center for Health Policy and Economics, clinical assistant professor at the Rutgers Pharmaceutical Industry Fellowship program, and assistant professor of clinical and administrative sciences at the Notre Dame of Maryland University College of Pharmacy, the first program of its kind created by a U.S. women’s college.

O’Brien has served on the boards of Pharmacy Quality Solutions, Kennedy Center Circles and the Congressional Chorus.

About the National Pharmaceutical Council

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.

National Pharmaceutical Council Appoints John M. O’Brien as President and CEO

), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists (

), a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network. 

The addition brings 17 new surgical specialists into The Network, greatly strengthening the organization’s expertise and knowledgebase in surgical specialties. The Network now has more than 200 surgical specialists, covering a wide range of specialties including: Gynecologic Oncology, Breast Surgery, Urology, Surgical Oncology, Colorectal Surgery, Thoracic Surgery, Orthopedic Oncology Surgery, Plastic Surgery and Head and Neck Surgery.

“With the addition of the physicians from TCRS, we have more than doubled the number of surgical specialists focused on colorectal surgery in The Network,” said Michael V. Seiden, MD, PhD, president, The US Oncology Network. “These physicians are meeting a critical need in cancer care, as 

 is the second leading cause of cancer deaths in the United States for men and women combined. While the increase in this specialty is dramatic, we are continuing to see accelerated growth in all disciplines as physicians look to The Network to help them cope with the increasingly challenging healthcare environment.”

The TCRS physicians typify physicians who have recently joined The Network, driven by the increasing complexity of the healthcare landscape and the impact of COVID-19. Within the past year, The Network welcomed 131 new physicians and 22 advanced practice providers into the organization, significantly increasing the availability of advanced cancer care in local communities while strengthening these providers’ ability to remain independent and viable.

More and more physicians are turning to The Network to leverage the many benefits that empower practices to succeed during uncertain times. Access to experts in community care, clinical and business consulting services, and innovative technologies that support high-quality care, efficient drug management, and revenue cycle optimization enable practices to successfully meet constantly changing challenges. 

—evidence-based treatment guidelines developed by physicians and clinicians in The Network along with the National Comprehensive Cancer Network®. As part of The Network, providers can also collaborate with more than 1,900 physicians and clinicians, sharing expertise and best practices. Additionally, The Network advocates for and negotiates with payers, legislators and manufacturers, leveraging its substantial resources on behalf of member practices.

“Joining Texas Oncology and uniting with The US Oncology Network provides us tremendous value, giving us access to vast resources and expertise,” said Dale Burleson, M.D., medical director of Texas Oncology’s new colorectal surgery division. “We are excited to benefit from the many services and technologies The Network offers that will allow us to continue to focus on providing our patients with high-quality care and optimal outcomes.”

The 17 board-certified single-specialty colorectal physicians are experts in the surgical and non-surgical treatment of colon and rectal problems. They have exceptional credentials, proven experience and prominent reputations in the medical community. 

As innovators in advanced colorectal care, the physicians performed more robotic, laparoscopic and minimally invasive colorectal procedures than any other practice in North Texas. They are also intimately involved in training and equipping the next generation of colorectal physicians. With 19 convenient locations that span several counties, most patients will not have far to travel for care.

“The addition of TCRS physicians provides benefits to Texas Oncology, most notably our ability to provide patients accessibility to high-quality, colorectal care right in their own communities and more opportunities to participate in value-based care opportunities, outcomes benchmarking and development of best practices, as well as groundbreaking clinical trials and research,” said 

, practice president, Texas Oncology. “Their expertise will be invaluable as we collaborate across our practice and The Network to advance care for colorectal diseases and disorders.”

 (The Network) helps more than 1,380 independent physicians deliver value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides practices with access to coordinated resources, best business practices, and the experience, infrastructure and support of 

. This collaboration allows the providers in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. The Network is committed to the success of independent practices, everywhere.

By joining The Network, these physicians contribute to the expansion of colorectal services in Texas.

US Oncology Network Enhances Surgical Expertise With Addition of Physicians From Texas Colon & Rectal Specialists 

Camber Pharmaceuticals is pleased to announce that it has launched Gemfibrozil

Tablets, which is the generic version of Lopid®

Gemfibrozil tablets are used together with proper diet to treat very high cholesterol and triglyceride levels and raise “good” cholesterol (HDL) in the blood.

Gemfibrozil Tabletsare available from Camber in 600 mg- 60 & 500 count bottles.

Camber Pharma Launches Generic Lopid®

®, the leading multimedia resource for pharmacy professionals, expands its Strategic Alliance Partnership (SAP) program with the addition of 

“With an extensive, impactful history, Roswell Park Comprehensive Cancer Center set the national standard for cancer care, research and education,” said Gil Hernandez, vice president of Pharmacy & Healthcare Communications, LLC, publisher of 

®. “Through this collective partnership, we look forward to making collaborative contributions intended to reduce cancer burdens for patients.”

Roswell Park Comprehensive Cancer Center, America's first cancer center, was founded in 1898 by Dr. Roswell Park. Roswell Park is the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center"​ and to serve as a member of the prestigious National Comprehensive Cancer Network. Over its long history, Roswell Park has made fundamental contributions to reducing the cancer burden and has successfully maintained an exemplary leadership role in setting the national standards for cancer care, research and education.

“With new approvals and constant streams of novel investigative therapies coming through more rapidly than ever, it’s critically important for the pharmacy community to embrace these developments and innovations quickly and effectively,” said Lijian “Leo” Cai, Pharm.D., chief pharmacy officer of Roswell Park Comprehensive Cancer Center. “We’re pleased to share insights from Roswell Park’s practice and research, and to help start these key conversations through our contributions to 

® SAP program is a community of advocacy groups and medical associations and institutions that foster collaboration and open exchange of information among trusted peers for the benefit of patients and their families. As part of this joint effort, 

® will work with the Roswell Park Comprehensive Cancer Center to inform and educate practicing pharmacists in 

® is the industry-leading multimedia pharmacy network of community, health system, oncology and specialty pharmacy platforms, providing practical clinical and professional information that pharmacists can use every day in their practices when counseling patients and interacting with other health care providers. Each issue and the website contain articles and features covering industry trends, medication errors, drug interactions, patient education, disease state management, patient counseling, product news, pharmacy law and more. Additionally, 

™ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 

About Roswell Park Comprehensive Cancer Center


Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at 

 or contact us at 1-800-ROSWELL (1-800-767-9355) or 

Pharmacy Times® Announces the Addition of Roswell Park Comprehensive Cancer Center to its Strategic Alliance Partnership Program

®, the leading multimedia pharmacy network, in conjunction with Parata Systems announces the 30 finalists for the 2019 Next-Generation Pharmacist® awards. This program honors remarkable pharmacists, student pharmacists, technicians, and industry advocates from 10 categories that include Civic Leader, Entrepreneur, Future Pharmacist, Health-System Pharmacist, and Rising Star.

“During this year’s Next-Generation Pharmacist® awards program, we are not only honoring these outstanding individuals selected for their dedication and accomplishments in the pharmacy industry, but we also are celebrating a decade of pharmacy inspiration and leadership,” said John Hydrusko, vice president of Pharmacy Healthcare Communications. “We are so thrilled to be part of this program every year with Parata Systems and look forward to awarding the 2019 Next-Generation Pharmacist®.”

Selected by a panel of distinguished judges, the 30 finalists represent the various roles across the pharmaceutical industry. Three finalists were selected in each category, signifying a true cross section of pharmacy practice settings, including large chain retailers, independent pharmacies, specialty pharmacies, military bases, health clinics, and educational institutions.

The 2019 Next-Generation Pharmacist® finalists are:

Curtis C. Gielow, PharmB, MHA, DLaw (Hon), Gielow Ventures LLC.

Suzanne Soliman, PharmD, BCMAS, Pharmacist Moms Group.

Rola Kaakeh, PharmD, CFPH, Salus Vitae Group.

Daniel S. Fuchs, RPh, Dicks Pharmacy and Fuchs Family Pharmacies.

Nikki Adams Bryant, PharmD, Adams Family Pharmacy.

Nashel Patel, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.

Sarah L. Anderson, PharmD, FCCP, BCPS, BCACP, University of Colorado and Denver Health Medical Center.

Kevin J. Colgan, MA, FASHP, University of Chicago Medicine.

Bruce R. Canaday, PharmD, FASHP, FAPha, St. Louis College of Pharmacy.

Susanne M. Hiland, PharmD, MBA, Walmart Health & Wellness.

Debra Goff, PharmD, FCCP, The Ohio State University Wexner Medical Center.

Mayank Amin, PharmD, RPh, MBA, Skippack Pharmacy.

Rhianna M. Fink, PharmD, BCACP, BC-ADM, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Clinica Family Health.

Maj. Miranda Debelevich, PharmD, BCGP, US Air Force.

Bejoy Paul Maniara, PharmD, BCPS, BCIDP, Northwell Health: Long Island Jewish Valley Stream.

Morgan Drew Greutman, PharmD, BCPS, Choctaw Nation Health Care Center.

Kirollos Hanna, PharmD, BCOP, Mayo Clinic College of Medicine and University of Minnesota Medical Center.

Benjamin Heiser, PharmD, MBA, CSP, Lumicera Health Services.

Tony E. Willoughby, PharmD, StratiFi Health.

Heather McCracken, Fairchild Air Force Base.

Jenny Bingham, PharmD, BCACP, SinfoniaRx.

Lisa Umfleet, RPh, BCGP CDE, Parkland Health Mart Pharmacy.

“These finalists represent a level of patient care that inspires the advancement of the profession," said Rob Kill, Parata CEO. "It’s inspiring to see everyone come together for this chance to meet and congratulate one another. We know the 10th year will be the best yet.”

The 10th annual gala will be held on Friday, Oct. 25, at the Hotel del Coronado in San Diego. Winners for each category will be announced, and one winner will be named the 2019 Next-Generation Pharmacist®. All selected finalists will be featured in the September print and online issues of 

Pharmacy Times®, the leading multimedia pharmacy network, in conjunction with Parata Systems announces the 30 finalists for the 2019 Next-Generation Pharmacist® awards.

Pharmacy Times and Parata Systems Reveal the 2019 Next-Generation Pharmacist Finalists

U.S. News & World Report, the global authority in rankings and consumer advice, and 

®, the leading multimedia resource for the pharmacy industry, today released the 

. Advil remains the No. 1 pick among pharmacists for treating headaches, while Zyrtec and Children's Claritin are new favorites for allergy relief in 2019.

® provides recommendations from thousands of pharmacists for nearly 800 over-the-counter brands across 135 product categories, giving pharmacists and patients a trusted resource to promote wellness, prevent and treat acute ailments and illnesses, and manage more complex conditions to improve patient outcomes.

With allergy symptoms still lingering and summer just around the corner, the list of top-recommended over-the-counter products helps consumers and their families stay healthy during any getaway. The No. 1 pharmacist- recommended brands include:

Insect Bite and Sting Management: After Bite

Topical Antibiotics/Antiseptics: Neosporin

To keep children healthy year-round, the 2019 top-recommended health products for common ailments like 

Children’s Allergy: Children’s Claritin

Children’s Analgesic: Children's Tylenol

Children’s Sore Throat: Chloraseptic Kids Sore Throat Spray

Children’s Cough/Cold Combination: Children’s Dimetapp

2019’s picks feature at-home testing products, including: the Omron digital thermometer, First Check cholesterol test and Omron blood pressure monitors.

“For three decades, consumers have turned to U.S. News to seek credible, quality rankings and information when making important health-care decisions,” said Angela Haupt, Assisting Managing Editor of Health at U.S. News. “Combining in-depth analysis and trusted journalism with the expertise of 

empowers consumers and their families with professional recommendations so the next trip to the drugstore is more informed and less overwhelming.”

® editor-in-chief, added: “We are proud to once again collaborate with U.S. News to offer the results of the survey to a larger audience and we appreciate the time and effort our pharmacists put in to share their recommendations. The OTC Guide® allows consumers access to trusted pharmacist insights on over-the-counter products.”

 and Pharmacy Times® began collaborating in 2012 to bring pharmacist recommendations to consumers nationwide. 

® evaluates pharmacists' insights and preferences through an annual research program conducted by 

HRA®—Healthcare Research and Analytics

, a consultative health care market research practice. Through the 

, consumers have an easy and searchable way to access the information produced by pharmacists’ recommendations. U.S. News displays brands that received at least 1% of pharmacists' votes, but only awards a “No. 1 Pharmacist Recommended Brand” designation to the top-ranked product in each category.

 to access the rankings and search pharmacist recommendations by symptom, product or category.

With allergy symptoms still lingering and summer just around the corner, the list of top-recommended over-the-counter products helps consumers and their families stay healthy during any getaway.

Press Releases